/

SER

Serina Therapeutics, Inc.Closed

1.82−0.12 −6.19%USD

NYSE American · as of Oct 13, 16:00 ETAfter hours 1.82 0.00%

Open

1.92

Prev close

1.94

Day range

1.781.97

52-week range

1.225.29

Volume

26.33K0.40×

Mkt cap

46.23M

P/E ttm

—

Fwd P/E

-1.73

EPS ttm

-1.87

Div yield

0.00%

Earnings

—

From 52w high

−65.60%

Price Chart

Yahoo Finance · delayed

SEROct 13, 2026O 1.92H 1.97L 1.78C 1.82−0.12 (−6.19%)Vol 26.30K

SMA 502.38
SMA 2002.13

1Y change −65.73% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SER Serina Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.78%
1 month: −18.02%
3 months: −12.92%
6 months: −5.70%
Year to date: −4.86%
1 year: −63.67%

Valuation & ownership

Market cap: 46.23M
Enterprise value: 26.96M
P/E (ttm): —
Forward P/E: -1.73
PEG ratio: —
Price / book: 2.47
Price / sales (ttm): —
EV / EBITDA: -1.05
EPS (ttm): -1.87
EPS (forward): -1.05
Beta (5y monthly): 0.16
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 25.40M
Float: 11.15M
Short % of float: 0.26%
Short ratio (days): 0.57
Held by insiders: 50.76%
Held by institutions: 5.55%
Avg volume (3m): 65.60K
50-day average: 2.38
200-day average: 2.13
52-week change: −63.67%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 32.0
vs 50-day SMA: −23.38%
vs 200-day SMA: −14.50%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.49%
Realised vol (20d, ann.): 53.0%
From 52-week high: −65.60%
From 52-week low: +49.18%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

9.50

+421.98% implied

Low 8.00Median 9.50High 11.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0
2m ago

DES

About Serina Therapeutics, Inc.

Yahoo Finance profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Sector: Healthcare
Industry: Biotechnology
Employees: 16
Headquarters: Huntsville, AL, United States
Website: serinatherapeutics.com
Officers: Dr. Balkrishan Gill Ph.D. Executive Co-Chairman of the Board
Mr. Steven A. Ledger CEO & Director
Dr. J. Milton Harris Ph.D. Co-Founder, Director Emeritus & Chair of Scientific Advisory Board
Dr. Srini Tenjarla Ph.D.

SEAS

Seasonality · SER

2018–2026 · monthly returns

Strongest month Jun +14.14%Weakest month Nov −13.51%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	69.9	-44.6	7.8	-6.2	1.1	5.4	3.1	21.0	-17.4	-9.0			−4.9%
2025	-6.2	6.0	13.9	11.3	-4.9	2.7	-10.1	-4.0	0.8	-6.7	-14.8	-55.1	−61.8%
2024	6.5	-7.1	-1.1	-33.9	5.7	1.8	-4.8	-12.5	-16.2	1.9	-23.0	-4.6	−63.6%
2023	35.9	-21.3	12.4	-12.5	-13.8	78.6	-18.3	4.1	-10.5	-11.8	-38.8	4.9	−30.3%
2022	-26.3	-14.7	24.7	0.8	-15.8	-20.6	22.9	-19.5	-1.4	6.8	-6.7	-1.4	−49.4%
2021	14.5	15.5	-19.4	-14.8	-8.0	22.0	-12.9	-23.7	-8.7	-13.8	-13.6	55.7	−28.3%
2020	-24.7	-16.1	-19.1	-9.2	33.9	-16.2	11.9	-16.7	-8.3	96.3	11.3	-14.1	−16.5%
2019	29.4	9.8	-4.7	12.6	-38.4	30.6	-20.2	-7.2	-27.9	-20.4	-9.0	28.2	−39.1%
2018												-44.6	−44.6%

INSD

Insider Activity · SER

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 6, 2026	Brannan Stephen KDirector	Purchase at price 2.03 per share.	1K	$2.03K
Jun 16, 2026	Bailey Gregory HughDirector	Conversion of Exercise of derivative security at price 2.25 per share.	8.44M	$18.98M
Jun 16, 2026	Venkatesan Jay RDirector	Conversion of Exercise of derivative security at price 2.25 per share.	224.2K	$504.34K
Jun 11, 2026	Wilson Karen JDirector	Purchase at price 1.74 - 1.77 per share.	10.1K	$17.75K
May 25, 2026	Ledger Steven AChief Executive Officer	Stock Award(Grant) at price 1.93 per share.	10.1K	$19.49K
May 21, 2026	Wilson Karen JDirector	Purchase at price 1.77 - 1.93 per share.	20K	$37.00K
May 21, 2026	Venkatesan Jay RDirector	Purchase at price 1.78 per share.	589	$1.05K
May 18, 2026	Marshall Richard Peter M.D., Ph.D.Director	Purchase at price 1.65 per share.	12.2K	$20.10K
Mar 30, 2026	Bailey Gregory HughDirector	Stock Award(Grant) at price 1.94 per share.	59.7K	$115.75K
Mar 30, 2026	Venkatesan Jay RDirector	Stock Award(Grant) at price 1.94 per share.	7.6K	$14.65K
Mar 22, 2026	Moreadith Randall W.Officer	Conversion of Exercise of derivative security at price 0.06 per share.	6.5K	$390
Mar 22, 2026	Moreadith Randall W.Officer	Sale at price 2.86 per share.	6.5K	$18.57K
Mar 18, 2026	Moreadith Randall W.Officer	Conversion of Exercise of derivative security at price 0.06 per share.	39K	$2.34K
Mar 18, 2026	Moreadith Randall W.Officer	Sale at price 2.50 per share.	39K	$97.50K
Feb 1, 2026	Moreadith Randall W.Officer	Conversion of Exercise of derivative security at price 0.06 per share.	6.5K	$390
Feb 1, 2026	Moreadith Randall W.Officer	Sale at price 3.03 per share.	6.5K	$19.68K
Jan 27, 2026	Moreadith Randall W.Officer	Conversion of Exercise of derivative security at price 0.06 per share.	6.5K	$390
Jan 27, 2026	Moreadith Randall W.Officer	Sale at price 2.72 per share.	6.5K	$17.68K
Jan 21, 2026	Moreadith Randall W.Officer	Conversion of Exercise of derivative security at price 0.06 per share.	2.5K	$150
Jan 21, 2026	Moreadith Randall W.Officer	Sale at price 2.95 per share.	2.5K	$7.38K

SER

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SER

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Serina Therapeutics, Inc.

Seasonality · SER

Insider Activity · SER

Congress Trades · SER

Investors Holding SER

Investors Holding SER

Congress Trades · SER

Seasonality · SER

Insider Activity · SER

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Serina Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News